Survival and GVHD analyses
| . | Study group (n = 22) . | Controls (n = 31) . | P value . |
|---|---|---|---|
| No. alive | 10 | 5 | |
| No. alive, progression free | 7 | 5 | |
| Median (range) days of follow-up, days | 55 (103-593) | 210 (42-1055) | .53 |
| GVHD, cumulative incidence (95% CI) | |||
| Acute grade II-IV GVHD at 100 days | 40.91% (20.18-60.71%) | 38.71% (21.67-55.49%). | .86 |
| Acute grade III-IV GVHD at 100 days | 9.1% (1.5-25.6%) | 12.90% (3.97-27.26%). | .66 |
| Chronic GVHD overall | 5% (0.30-19.55%) | 22.51% (8.48-40.61%). | .17 |
| . | Study group (n = 22) . | Controls (n = 31) . | P value . |
|---|---|---|---|
| No. alive | 10 | 5 | |
| No. alive, progression free | 7 | 5 | |
| Median (range) days of follow-up, days | 55 (103-593) | 210 (42-1055) | .53 |
| GVHD, cumulative incidence (95% CI) | |||
| Acute grade II-IV GVHD at 100 days | 40.91% (20.18-60.71%) | 38.71% (21.67-55.49%). | .86 |
| Acute grade III-IV GVHD at 100 days | 9.1% (1.5-25.6%) | 12.90% (3.97-27.26%). | .66 |
| Chronic GVHD overall | 5% (0.30-19.55%) | 22.51% (8.48-40.61%). | .17 |